Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Zenas BioPharma (NASDAQ: ZBIO) said management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 1:30 p.m. ET. A live webcast and archived replay will be available under Events and Presentations in the Investor & Media Relations section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – ZBIO
In the Feb 4 session, ZBIO gained 4.77%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -8.3% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Inducement grant | Neutral | +3.6% | Stock option inducement grant for a new employee under Nasdaq Rule 5635(c)(4). |
| Jan 05 | Phase 3 results | Positive | -51.9% | Obexelimab met primary and key secondary endpoints in Phase 3 INDIGO trial in IgG4-RD. |
| Dec 19 | Inducement grants | Neutral | +17.1% | Equity inducement option grants totaling 300,000 shares to new employees. |
| Dec 15 | Partner trial win | Positive | -19.7% | Partner InnoCare achieved primary endpoint in Phase 2b orelabrutinib SLE study. |
| Nov 12 | Earnings and update | Mixed | +1.7% | Q3 2025 results with clinical progress, major financings and going-concern disclosure. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent major clinical wins have sometimes been followed by sharp negative price reactions, while smaller corporate or financing updates showed modest positive or volatile responses.
Over the last few months, ZBIO has reported key clinical and financing milestones. Positive Phase 2 and Phase 3 results for obexelimab and orelabrutinib were noted on Oct 27, 2025 and Jan 5, 2026, yet the stock moved -51.86% after the positive Phase 3 INDIGO data. Inducement grant announcements on Dec 19, 2025 and Jan 16, 2026 saw moderate gains of 17.1% and 3.57%. Q3 2025 earnings on Nov 12, 2025 brought a smaller 1.7% rise. Today’s conference appearance fits the pattern of corporate updates rather than major data catalysts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced management’s presentation at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 1:30 p.m. ET.
A live webcast and archived replay of the Company’s presentation can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Investor and Media Contact:
Argot Partners
Zenas@argotpartners.com
